MX375202B - Composiciones adyuvantes novedosas. - Google Patents

Composiciones adyuvantes novedosas.

Info

Publication number
MX375202B
MX375202B MX2016016410A MX2016016410A MX375202B MX 375202 B MX375202 B MX 375202B MX 2016016410 A MX2016016410 A MX 2016016410A MX 2016016410 A MX2016016410 A MX 2016016410A MX 375202 B MX375202 B MX 375202B
Authority
MX
Mexico
Prior art keywords
adjuvant compositions
novel adjuvant
formulations
adjuvant
compositions
Prior art date
Application number
MX2016016410A
Other languages
English (en)
Inventor
Cedo Martin Bagi
Tedd Alan Childers
Paul Joseph Dominowski
Richard Lee Krebs
Ramasamy Mannar Mannan
Mary Kathryn Olsen
James Richard Thompson
Risini Dhammika Weeratna
Robert John Yancey Jr
Shucheng Zhang
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of MX375202B publication Critical patent/MX375202B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/012—Coccidia antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24351—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se refiere a una composición de adyuvante, caracterizada porque comprende un oligonucleótido inmunoestimulador, un polímero de ácido poliacrílico y al menos dos de los siguientes; a. bromuro de dimetil dioctadeciol amonio (DDA); b. un estero; c. Acetato de N-(2-despxo-2-Lleucilamino-ß-D-glucopiranosil)-N.octadecildodecanamida, en donde l oligonucleótido inmunoestimulador comprende ORNo CpG ODN, y en dond ela composición de adyuvante está libre de saponina.
MX2016016410A 2008-06-27 2009-06-24 Composiciones adyuvantes novedosas. MX375202B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7623208P 2008-06-27 2008-06-27
US21455709P 2009-04-24 2009-04-24
PCT/IB2009/052724 WO2009156960A2 (en) 2008-06-27 2009-06-24 Novel adjuvant compositions

Publications (1)

Publication Number Publication Date
MX375202B true MX375202B (es) 2025-03-06

Family

ID=41445049

Family Applications (6)

Application Number Title Priority Date Filing Date
MX2016016408A MX368220B (es) 2008-06-27 2009-06-24 Composiciones adyuvantes novedosas.
MX2016016410A MX375202B (es) 2008-06-27 2009-06-24 Composiciones adyuvantes novedosas.
MX2013014771A MX349720B (es) 2008-06-27 2009-06-24 Composiciones adyuvantes novedosas.
MX2010014026A MX2010014026A (es) 2008-06-27 2009-06-24 Composiciones adyuvantes novedosas.
MX2013014772A MX344311B (es) 2008-06-27 2009-06-24 Composiciones adyuvantes novedosas.
MX2019011253A MX2019011253A (es) 2008-06-27 2010-12-16 Composiciones adyuvantes novedosas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016016408A MX368220B (es) 2008-06-27 2009-06-24 Composiciones adyuvantes novedosas.

Family Applications After (4)

Application Number Title Priority Date Filing Date
MX2013014771A MX349720B (es) 2008-06-27 2009-06-24 Composiciones adyuvantes novedosas.
MX2010014026A MX2010014026A (es) 2008-06-27 2009-06-24 Composiciones adyuvantes novedosas.
MX2013014772A MX344311B (es) 2008-06-27 2009-06-24 Composiciones adyuvantes novedosas.
MX2019011253A MX2019011253A (es) 2008-06-27 2010-12-16 Composiciones adyuvantes novedosas.

Country Status (29)

Country Link
US (6) US8580280B2 (es)
EP (4) EP2310046B1 (es)
JP (5) JP5659332B2 (es)
KR (1) KR101333852B1 (es)
CN (4) CN102076358B (es)
AR (1) AR072378A1 (es)
AU (1) AU2009263759B2 (es)
BR (2) BR122021025097B1 (es)
CA (3) CA2960846C (es)
CL (1) CL2010001360A1 (es)
CO (1) CO6331297A2 (es)
CY (2) CY1117650T1 (es)
DK (2) DK3056214T3 (es)
ES (2) ES2728949T3 (es)
HR (1) HRP20190876T1 (es)
HU (2) HUE043493T2 (es)
LT (1) LT3056214T (es)
ME (1) ME01199B (es)
MX (6) MX368220B (es)
NZ (5) NZ727616A (es)
PH (2) PH12014501835A1 (es)
PL (2) PL3056214T3 (es)
PT (1) PT3056214T (es)
RU (1) RU2510280C2 (es)
SI (2) SI2310046T1 (es)
TW (4) TWI622400B (es)
UY (1) UY31942A (es)
WO (1) WO2009156960A2 (es)
ZA (1) ZA201007835B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8444989B1 (en) * 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
CN102076358B (zh) * 2008-06-27 2016-08-17 硕腾有限责任公司 新颖的佐剂组合物
TWI351288B (en) * 2008-07-04 2011-11-01 Univ Nat Pingtung Sci & Tech Cpg dna adjuvant in avian vaccines
MY160201A (en) * 2008-12-09 2017-02-28 Coley Pharm Group Inc Immunostimulatory oligonucleotides
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
EP2464341B1 (en) * 2009-08-12 2022-07-06 Sublimity Therapeutics Limited Immunomodulatory compositions comprising a polymer matrix and an oil phase
FR2957803B1 (fr) * 2010-03-24 2012-06-01 Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic Diluants adjuvants de vaccins vivants pour maladies porcines
BR112012030337B1 (pt) * 2010-05-28 2021-04-27 Coley Pharmaceutical Group, Inc Vacina compreendendo um ou mais oligonucleotídeo(s) de cpg isolado(s) ou um agonista de tlr e colesterol, e uso da mesma
PE20140576A1 (es) * 2011-06-10 2014-05-24 Novartis Ag Vacunas bovinas y metodos
TR201808733T4 (tr) * 2011-10-03 2018-07-23 Mx Adjuvac Ab Kanser tedavisini ve gıda ile ilgili bileşikleri içeren tıp alanlarında amfipatik veya hidrofobik moleküller için taşıyıcı olarak nano-parçacıklar, preparasyon için proses ve bunların kullanımı.
EP4218808A3 (en) 2012-03-12 2023-08-09 Advanced BioAdjuvants, LLC Adjuvant and vaccine compositions
CA2896293C (en) 2012-12-28 2023-11-07 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition comprising mycoplasma antigens
PL2938747T3 (pl) 2012-12-28 2019-11-29 Boehringer Ingelheim Vetmedica Gmbh Sposób wytwarzania szczepionki przeciwko mykoplazmie
CN103127495B (zh) * 2013-01-28 2015-04-08 重庆市畜牧科学院 二联灭活苗的制剂及其制备方法
CN109078179A (zh) * 2013-09-05 2018-12-25 硕腾服务有限责任公司 Hendra和Nipah病毒G糖蛋白免疫原性组合物
RU2730011C2 (ru) * 2013-09-19 2020-08-14 Зоэтис Сервисиз Ллс Адъюванты на масляной основе
WO2015057777A1 (en) 2013-10-17 2015-04-23 Zoetis Llc Methods and compositions for treatment of s. equi infection
CN115154596B (zh) * 2013-11-26 2025-06-17 硕腾服务有限责任公司 诱导免疫应答的组合物
US10195261B2 (en) 2014-11-26 2019-02-05 VaxLiant, LLC Adjuvant compositions and related methods
MX388527B (es) * 2014-11-26 2025-03-20 Huvepharma Inc Composiciones adyuvantes y metodos relacionados.
FI3244920T3 (fi) * 2015-01-16 2023-08-04 Zoetis Services Llc Suu- ja sorkkatautirokote
MX390860B (es) * 2015-03-24 2025-03-21 Huvepharma Inc Composiciones adyuvantes y metodos relacionados.
CN104771754B (zh) * 2015-04-02 2018-02-13 武汉科前生物股份有限公司 一种猪圆环病毒2型灭活疫苗水性佐剂及应用
CN106267183B (zh) * 2015-06-09 2023-02-28 普莱柯生物工程股份有限公司 含有佐剂的活疫苗组合物及其制备方法和应用
CN106344920B (zh) * 2015-07-16 2020-11-27 普莱柯生物工程股份有限公司 一种疫苗用佐剂及其应用
US10456459B2 (en) 2015-07-20 2019-10-29 Zoetis Services Llc Liposomal adjuvant compositions
HUE054422T2 (hu) * 2015-07-20 2021-09-28 Zoetis Services Llc Liposzómás adjuváns készítmények
WO2017068482A1 (en) * 2015-10-19 2017-04-27 Cadila Healthcare Limited New adjuvant and vaccine composition containing the same
CA3010977A1 (en) 2016-01-11 2017-07-20 Zoetis Services Llc Novel cross protective vaccine compositions for porcine epidemic diarrhea virus
US11013798B2 (en) 2016-03-21 2021-05-25 South Dakota Board Of Regents Orf virus-based platform for vaccine delivery
UA126562C2 (uk) 2016-06-02 2022-11-02 Зоетіс Сервісіз Ллс Вакцина для домашньої птиці проти інфекційного бронхіту
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
GB201703529D0 (en) 2017-03-06 2017-04-19 Cambridge Entpr Ltd Vaccine composition
US10092604B1 (en) * 2017-12-21 2018-10-09 Bioceuticals Pte. Ltd. Methods for treatment of skin infectious diseases using microorganisms
CA3093709C (en) 2018-03-16 2024-03-26 Zoetis Services Llc Peptide vaccines against interleukin-31
CN108853493A (zh) * 2018-07-26 2018-11-23 中国人民解放军陆军军医大学 麦冬皂苷d及其纳米乳在制备疫苗佐剂中的应用
BR112021001420A2 (pt) 2018-07-27 2021-05-04 Research Development Foundation polipeptídeos imunogênicos quiméricos
WO2020055503A1 (en) 2018-09-14 2020-03-19 Massachusetts Institute Of Technology Nanoparticle vaccine adjuvant and methods of use thereof
CN109675028A (zh) * 2019-03-01 2019-04-26 龙阔（苏州）生物工程有限公司 疫苗佐剂及其制备方法和应用及猪繁殖与呼吸综合征疫苗
PH12022550081A1 (en) * 2019-07-12 2023-04-12 Res Found Dev Ehrlichia vaccines and immunogenic compositions
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
MX2022016382A (es) * 2020-06-19 2023-01-30 Kimberly Clark Co Extractos que contienen saponina preparados a partir de hesperaloe utiles en el tratamiento de animales no humanos.
JP2023531395A (ja) * 2020-06-19 2023-07-24 キンバリー クラーク ワールドワイド インコーポレイテッド 非ヒト動物の治療において有用なヘスペラロエから調製した抽出物を含むサポニン
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
TWI884296B (zh) * 2020-08-11 2025-05-21 美商碩騰服務公司 抗冠狀病毒疫苗
CN114848807A (zh) * 2021-02-04 2022-08-05 洛阳赛威生物科技有限公司 一种蜂胶佐剂组合物、及其制备方法以及应用
US20230109193A1 (en) * 2021-10-02 2023-04-06 Massachusetts Institute Of Technology Synergistic Combination of Alum and Non-Liposome, Non-Micelle Particle Vaccine Adjuvants
AU2024220779A1 (en) * 2023-02-16 2025-09-04 Vaxinano Vaccine composition comprising a system for delivering an inactivated whole bacterium via cationic polysaccharide nanoparticles without any adjuvant
US12226468B2 (en) 2023-06-26 2025-02-18 Research Development Foundation Immunoreactive peptides
CN116747312B (zh) * 2023-07-21 2025-08-08 辽宁成大生物股份有限公司 一种疫苗冻干保护剂、制剂及制备方法
CN121360223A (zh) * 2024-07-19 2026-01-20 硕腾服务有限责任公司 流感疫苗

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4264587A (en) * 1979-08-01 1981-04-28 Pedersen Niels C Vaccine for preventing persistent feline leukemia viremia in cats
NZ221306A (en) * 1986-08-15 1990-02-26 Commw Scient Ind Res Org 2-component immunoadjuvant comprising a mycobacterial free immunoadjuvant oil and a polycationic polyelectrolyte immunoadjuvant and vaccines thereof
US5084269A (en) 1986-11-06 1992-01-28 Kullenberg Fred W Adjuvant for dose treatment with antigens
ATE60999T1 (de) 1986-12-19 1991-03-15 Duphar Int Res Dimethyldioctadecylammoniumbromid enthaltende stabilisierte adjuvanssuspension.
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) * 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
RU1615918C (ru) 1989-05-22 1995-07-09 Всероссийский научно-исследовательский институт защиты животных Адъювант
AU3441693A (en) * 1992-01-06 1993-08-03 Smithkline Beecham Corporation Feline leukemia virus vaccines
ZA936095B (en) 1992-08-21 1994-03-14 Univ Melbourne Cytokine applications.
US6764682B1 (en) 1994-06-16 2004-07-20 Aventis Pasteur Limited Adjuvant compositions containing more than one adjuvant
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6846489B1 (en) * 1995-04-25 2005-01-25 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
EP0930893B1 (en) 1996-10-11 2005-04-13 The Regents of The University of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
EP0855184A1 (en) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
AU738513B2 (en) 1997-02-28 2001-09-20 University Of Iowa Research Foundation, The Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
CA2289253A1 (en) 1997-04-30 1998-11-05 Merieux Oravax Anti-helicobacter vaccine composition for use by the subdiaphragmatic systemic route, and combined mucosal/parenteral immunization method
WO1998051278A2 (en) 1997-05-14 1998-11-19 Inex Pharmaceuticals Corporation High efficiency encapsulation of charged therapeutic agents in lipid vesicles
JP4101888B2 (ja) 1997-06-06 2008-06-18 ダイナバックス テクノロジーズ コーポレイション 免疫刺激オリゴヌクレオチド、その組成物およびその使用方法
JP2001520205A (ja) * 1997-10-20 2001-10-30 バイエル・コーポレーシヨン ネオスポラワクチン
EP0953641A3 (en) * 1998-03-26 2002-03-13 Pfizer Products Inc. Polynucleotide molecules encoding neospora proteins
CA2328406A1 (en) 1998-05-14 1999-11-18 Hermann Wagner Methods for regulating hematopoiesis using cpg-oligonucleotides
IL139813A0 (en) 1998-05-22 2002-02-10 Loeb Health Res Inst At The Ot Methods and products for inducing mucosal immunity
US20040247662A1 (en) 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
CA2340174C (en) 1998-08-10 2011-01-04 Antigenics Llc Compositions of cpg and saponin adjuvants and methods thereof
AU769539B2 (en) 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
CA2363141C (en) 1999-02-26 2010-04-06 Novartis Vaccines And Diagnostics, Inc. Microemulsions with adsorbed macromolecules and microparticles
AU4188100A (en) 1999-04-08 2000-11-14 Gregory M. Glenn Dry formulation for transcutaneous immunization
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
CN1227030C (zh) 1999-04-19 2005-11-16 史密丝克莱恩比彻姆生物有限公司 包含皂甙和免疫刺激寡核苷酸的佐剂组合物
DE60013591T2 (de) 1999-04-29 2005-02-03 Coley Pharmaceutical Gmbh Screening nach modulatoren der funktion von immunstimulatorischer dna
DE60131430T2 (de) 2000-01-14 2008-10-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
WO2001095935A1 (en) 2000-01-20 2001-12-20 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
EE200200444A (et) 2000-02-21 2003-12-15 Pharmexa A/S Meetod autoloogse beeta-amüloidvaigu in vivo mahasurumiseks, amüloidogeense polüpeptiidi analoog, seda kodeeriv nukleiinhappefragment ning kasutamineimmunogeense kompositsiooni valmistamiseks
JP2003531915A (ja) 2000-05-01 2003-10-28 ハイブリドン・インコーポレイテッド ヌクレオシドの位置的修飾によるオリゴヌクレオチドＣｐＧ誘導性免疫刺激の調節
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
GB0025577D0 (en) 2000-10-18 2000-12-06 Smithkline Beecham Biolog Vaccine
AU2001297693A1 (en) 2000-12-08 2002-09-12 Coley Pharmaceutical Gmbh Cpg-like nucleic acids and methods of use thereof
US7244438B2 (en) 2001-01-05 2007-07-17 Intercell Ag Uses for polycationic compounds
US7713942B2 (en) 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
WO2002080648A2 (en) 2001-04-05 2002-10-17 Chiron Corporation Mucosal boosting following parenteral priming
US7105495B2 (en) 2001-04-30 2006-09-12 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
JP4188092B2 (ja) 2001-05-21 2008-11-26 インターツェル・アクチェンゲゼルシャフト 免疫促進性オリゴデオキシ核酸分子
WO2002102307A2 (en) 2001-06-15 2002-12-27 Ribapharm Nucleoside vaccine adjuvants
WO2003004051A2 (en) * 2001-07-02 2003-01-16 Pfizer Products Inc. Mycoplasma hyopneumoniae vaccine and methods for reducing mycoplasma bovis pneumonia in cattle
TNSN03155A1 (fr) * 2001-07-02 2005-12-23 Pfizer Prod Inc Vaccination unidose avec mycoplasma hyopneumoniae
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
CA2456193A1 (en) 2001-08-03 2003-03-27 Medarex, Inc. Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies
WO2003014316A2 (en) 2001-08-07 2003-02-20 Dynavax Technologies Corporation Immunomodulatory compositions, formulations, and methods for use thereof
US20030138434A1 (en) 2001-08-13 2003-07-24 Campbell Robert L. Agents for enhancing the immune response
CN1604795B (zh) 2001-08-17 2010-05-26 科勒制药股份公司 具有提高的活性的组合基序免疫刺激寡肽
KR20040031015A (ko) 2001-08-28 2004-04-09 화이자 프로덕츠 인크. 마이코플라즈마 보비스 시험감염 모델, 엠. 보비스 투여방법 및 폐렴성 폐 병변 유도 방법
DE60234375D1 (de) 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
US20030119774A1 (en) 2001-09-25 2003-06-26 Marianna Foldvari Compositions and methods for stimulating an immune response
GB0123580D0 (en) * 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
WO2003030934A2 (en) 2001-10-06 2003-04-17 Merial Limited Cpg formulations and related methods
US7276489B2 (en) 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
US20030125292A1 (en) 2001-11-07 2003-07-03 Sean Semple Mucoscal vaccine and methods for using the same
WO2003047602A1 (en) 2001-12-07 2003-06-12 Intercell Ag Immunostimulatory oligodeoxynucleotides
JP2005526497A (ja) 2002-02-04 2005-09-08 ビオミラ，インコーポレーテッド 免疫刺激性、共有結合性脂質化オリゴヌクレオチド
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
WO2003070190A2 (en) 2002-02-19 2003-08-28 Syntherica Corporation Surrogate antibodies and methods of preparation and use thereof
AU2003230806B2 (en) 2002-04-04 2009-05-07 Zoetis Belgium S.A. Immunostimulatory G,U-containing oligoribonucleotides
AU2003262379A1 (en) 2002-04-16 2003-11-03 Auburn University TRANSIENT AND/OR PERMANENT MODIFICATION OF SEXUAL BEHAVIOR AND/OR FERTILITY USING RECOMBINANT CHIMERIC GnRH
MXPA04010415A (es) 2002-04-22 2005-02-17 Bioniche Life Sciences Inc Composiciones oligonucleotdias y su uso para la modulacion de respuestas inmunes.
KR100456681B1 (ko) 2002-05-22 2004-11-10 주식회사 대웅 박테리아의 염색체 ｄｎａ 파쇄물과 비독성리포폴리사카라이드를 포함하는 면역강화 및 조절 조성물
EP1507850A1 (en) 2002-05-28 2005-02-23 MERCK PATENT GmbH A method for generating antigen-presenting cells
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
SE0201701D0 (sv) 2002-06-05 2002-06-05 Gotovax Ab Treatment of epithelial tumors and infections
AU2003243409A1 (en) 2002-06-05 2003-12-22 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids
AU2003263963A1 (en) 2002-08-01 2004-02-23 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Method of treating inflammatory arthropathies with suppressors of cpg oligonucleotides
CN1723172A (zh) 2002-11-05 2006-01-18 詹姆士·哈代国际金融公司 用于生产硅酸钙水合物的方法和设备
HRP20050660A2 (en) * 2003-01-29 2006-02-28 Pfizer Products Inc. Canine vaccines against bordetella bronchiseptica
AU2003900767A0 (en) * 2003-02-21 2003-03-13 St Vincent's Hospital Sydney Limited Idiotypic vaccine
JP5022028B2 (ja) 2003-03-26 2012-09-12 サイトス・バイオテクノロジー・アクチェンゲゼルシャフト メラン−ａペプチドアナログ−ウイルス様粒子コンジュゲート
PL1613346T3 (pl) 2003-04-04 2013-03-29 Zoetis Services Llc Poddane mikrofluidyzacji emulsje typu olej w wodzie i kompozycje szczepionek
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
GB0323965D0 (en) * 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions
DE202005022108U1 (de) * 2004-03-09 2013-11-12 Novartis Vaccines And Diagnostics, Inc. Influenza-Virus-Impfstoffe
WO2005097181A1 (en) * 2004-04-05 2005-10-20 Pfizer Products Inc. Microfluidized oil-in-water emulsions and vaccine compositions
EP1799252A4 (en) * 2004-10-06 2009-01-21 Agri Biotech Pty Ltd ANTIBODY PRODUCTION PROCESS
GB0426481D0 (en) * 2004-12-02 2005-01-05 Vaccine Technology Ltd Composition
AU2006231916A1 (en) 2005-04-07 2006-10-12 Pharmacia & Upjohn Company Llc Formulations and process for production of Bordetella bronchiseptica p68 antigen and vaccines
US20060241076A1 (en) * 2005-04-26 2006-10-26 Coley Pharmaceutical Gmbh Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
EP1945254A1 (en) * 2005-10-07 2008-07-23 Pfizer Products Incorporated Vaccines and methods to treat canine influenza
ES2564241T3 (es) * 2005-12-02 2016-03-21 Glaxosmithkline Biologicals Sa Nanopartículas para su uso en composiciones inmunogénicas
PL1991266T3 (pl) 2006-01-26 2013-11-29 Zoetis Services Llc Nowe kompozycje adiuwantów glikolipidowych
CA2637837A1 (en) * 2006-01-26 2007-08-09 Hx Diagnostics, Inc. Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof
EP2091561A2 (en) 2006-12-15 2009-08-26 Schering-Plough Ltd. Method for replicating influenza virus in culture
WO2008074487A2 (en) * 2006-12-19 2008-06-26 Novosom Ag Lipids and lipid assemblies comprising transfection enhancer elements
US20080292663A1 (en) 2007-05-22 2008-11-27 Gerber Jay D Adjuvant compositions and methods for delivering vaccines
CL2008001806A1 (es) 2007-06-20 2008-09-05 Wyeth Corp Composicion de vacuna en emulsion agua en aceite que comprende un antigeno y un adyuvante en la fase acuosa; y metodo de elaboracion.
CN102076358B (zh) * 2008-06-27 2016-08-17 硕腾有限责任公司 新颖的佐剂组合物
PL2402032T3 (pl) 2009-02-27 2020-03-31 Toray Industries, Inc. Kompozycja immunogenna
US10456459B2 (en) * 2015-07-20 2019-10-29 Zoetis Services Llc Liposomal adjuvant compositions

Also Published As

Publication number Publication date
HK1201444A1 (zh) 2015-09-04
HUE043493T2 (hu) 2019-08-28
UY31942A (es) 2010-01-29
JP2015143244A (ja) 2015-08-06
US11896666B2 (en) 2024-02-13
JP2014111619A (ja) 2014-06-19
JP6038211B2 (ja) 2016-12-07
BR122021025097B1 (pt) 2022-07-26
BRPI0913954B1 (pt) 2022-04-05
NZ727616A (en) 2018-06-29
JP2017061484A (ja) 2017-03-30
CN104758929B (zh) 2018-05-25
SI3056214T1 (sl) 2019-06-28
JP5824538B2 (ja) 2015-11-25
ES2569907T3 (es) 2016-05-13
ZA201007835B (en) 2012-01-25
US12521433B2 (en) 2026-01-13
PL2310046T3 (pl) 2016-09-30
PH12014501836A1 (en) 2016-03-07
CA2960734C (en) 2021-08-24
CA2960846A1 (en) 2009-12-30
NZ589079A (en) 2012-11-30
CA2960846C (en) 2020-08-25
CN104001170B (zh) 2016-08-24
MX368220B (es) 2019-09-24
TW201544121A (zh) 2015-12-01
MX2019011253A (es) 2019-11-01
US9662385B2 (en) 2017-05-30
TWI614027B (zh) 2018-02-11
NZ602945A (en) 2014-05-30
CL2010001360A1 (es) 2011-04-08
US20170304434A1 (en) 2017-10-26
CA2960734A1 (en) 2009-12-30
SI2310046T1 (sl) 2016-05-31
AU2009263759A1 (en) 2009-12-30
TWI622401B (zh) 2018-05-01
NZ709547A (en) 2017-01-27
CA2723786C (en) 2020-04-28
KR101333852B1 (ko) 2013-11-27
CY1121789T1 (el) 2020-07-31
WO2009156960A2 (en) 2009-12-30
TWI513464B (zh) 2015-12-21
DK2310046T3 (da) 2016-04-25
KR20110010817A (ko) 2011-02-07
CA2723786A1 (en) 2009-12-30
PT3056214T (pt) 2019-06-12
US20090324641A1 (en) 2009-12-31
ME01199B (me) 2013-03-20
CN104001169A (zh) 2014-08-27
EP3056214B1 (en) 2019-04-03
EP2310046B1 (en) 2016-03-09
HK1201445A1 (en) 2015-09-04
RU2510280C2 (ru) 2014-03-27
JP2014111620A (ja) 2014-06-19
WO2009156960A9 (en) 2010-09-30
AR072378A1 (es) 2010-08-25
EP3725328A3 (en) 2020-12-23
JP5882370B2 (ja) 2016-03-09
TW201540311A (zh) 2015-11-01
PL3056214T3 (pl) 2019-09-30
CN102076358B (zh) 2016-08-17
JP2011525911A (ja) 2011-09-29
HUE028921T2 (en) 2017-01-30
CN104001169B (zh) 2016-03-23
NZ621834A (en) 2015-10-30
HRP20190876T1 (hr) 2019-07-12
EP3725328A2 (en) 2020-10-21
US8580280B2 (en) 2013-11-12
JP6294938B2 (ja) 2018-03-14
US10238736B2 (en) 2019-03-26
TWI622400B (zh) 2018-05-01
WO2009156960A3 (en) 2010-06-17
EP2310046A2 (en) 2011-04-20
HK1211870A1 (en) 2016-06-03
AU2009263759B2 (en) 2013-06-06
MX349720B (es) 2017-08-09
US20190008953A1 (en) 2019-01-10
CN104001170A (zh) 2014-08-27
JP5659332B2 (ja) 2015-01-28
PH12014501835A1 (en) 2016-03-07
EP3056214A1 (en) 2016-08-17
US10940202B2 (en) 2021-03-09
EP3552625A1 (en) 2019-10-16
TW201544122A (zh) 2015-12-01
MX344311B (es) 2016-12-13
TW201014601A (en) 2010-04-16
CN104758929A (zh) 2015-07-08
CN102076358A (zh) 2011-05-25
US20210338810A1 (en) 2021-11-04
CY1117650T1 (el) 2017-04-26
LT3056214T (lt) 2019-06-10
BRPI0913954A2 (pt) 2021-04-06
DK3056214T3 (da) 2019-05-13
MX2010014026A (es) 2011-02-15
RU2010149495A (ru) 2012-08-10
CO6331297A2 (es) 2011-10-20
US20240358825A1 (en) 2024-10-31
ES2728949T3 (es) 2019-10-29
US20140056940A1 (en) 2014-02-27

Similar Documents

Publication Publication Date Title
MX375202B (es) Composiciones adyuvantes novedosas.
MX352324B (es) Vacunas multivalentes de nanovehiculos sinteticos.
EA201001491A1 (ru) Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
AU2015296298A8 (en) Flagellin-based agents and uses including effective vaccination
IN2012DN02736A (es)
PH12015500092A1 (en) Compositions for immunising against staphylococcus aureus
CR11731A (es) Composiciones y procedimientos para su preparación y uso
EA201370018A1 (ru) Составы рифаксимина и их применение
MX2018009945A (es) Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
HN2011003011A (es) Composiciones sublinguales de dexmedetomidina y metodos de uso de ellas
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
BR112014014678A2 (pt) composições oftálmicas compreendendo copolímeros de enxertia de polivinil caprolactama-acetato de polivinila-polietileno glicol
MX347471B (es) Vacunas que comprenden colesterol y cpg como moleculas portadoras-adyuvantes unicas.
PH12015501637A1 (en) Inactivated dengue virus vaccine with aluminium-free adjuvant
EA201500054A1 (ru) Аттенуированные вакцины против streptococcus suis и способы их получения и применения
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
WO2014100857A8 (en) Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
EA201290319A1 (ru) Применение источника l3 и/или l5 в качестве вакцины или диагностического средства для паразитарного заболевания
BRPI1008721A2 (pt) métodos para tratamento terapêutico ou profiláctico de hiv, método profilático, composição terapêutica ou preparação, associação de vacina terapêutica, kit para implantação de método terapêutico
WO2012103444A3 (en) Immunogenic compositions and reagents for preparing
MX385188B (es) Vacuna de rinitis equina.
EA201200538A1 (ru) Арабиногалактан для повышения приобретенного иммунного ответа
UA104138C2 (en) Novel adjuvant compositions
TR201907091T4 (tr) Yeni adjuvan kompozisyonları.
TN2010000338A1 (en) Vaccine comprising a ribosomal protein extract (rpe) and optionally a th1-promoting adjuvant